Etalanetug clinical trials
Also written E2814.
How each study uses etalanetug is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- E2814
- 5
Studies by the year they started
5 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2019 | 1 |
| 2021 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 2
Eisai Inc. (3) · Washington University School of Medicine (2)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test etalanetug.
- Dec 2026A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's DiseasePhase 2 · Eisai Inc.
Studies
Open first, then newest update. How each study uses etalanetug is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)Active, not recruitingPhase 2/3Washington University School of MedicineNCT05269394Written as E2814
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001Active, not recruitingPhase 2/3Washington University School of MedicineNCT01760005Written as E2814
- A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's DiseaseActive, not recruitingPhase 2Eisai Inc.NCT06602258Written as E2814
- A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's DiseaseCompletedPhase 1/2Eisai Inc.NCT04971733Written as E2814
- A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy ParticipantsCompletedPhase 1Eisai Inc.NCT04231513Written as E2814
Codes
What other systems call etalanetug · ClinicalTrials.gg INT018015
- UNII (FDA) TE9GZ84LVNETALANETUGOne source FDA
- NCI Thesaurus C206912EtalanetugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | TE9GZ84LVN | ETALANETUG | One source FDA |
| NCI Thesaurus | C206912 | Etalanetug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.